Makers Laboratories Limited (MAKERSL.BO)
- Previous Close
144.55 - Open
144.00 - Bid 133.30 x --
- Ask 132.00 x --
- Day's Range
128.60 - 144.00 - 52 Week Range
122.00 - 230.00 - Volume
1,654 - Avg. Volume
3,222 - Market Cap (intraday)
786.521M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
12.58 - EPS (TTM)
10.60 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 1, 2019
- 1y Target Est
--
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers general health therapeutic products, such as acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, antiinflammatory, analgesic, anti-spasmodic, anti-malarial, and anti-thyroid. It also provides cough and cold control, digestives, neurotonics, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties drugs. The company sells its products under the Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin brand names. It distributes its products through agents, stockiest, doctors, and retailers. Makers Laboratories Limited was incorporated in 1984 and is based in Mumbai, India.
www.makerslabs.com121
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: MAKERSL.BO
View MorePerformance Overview: MAKERSL.BO
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAKERSL.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAKERSL.BO
View MoreValuation Measures
Market Cap
786.52M
Enterprise Value
778.72M
Trailing P/E
12.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.69
Price/Book (mrq)
1.11
Enterprise Value/Revenue
0.68
Enterprise Value/EBITDA
4.43
Financial Highlights
Profitability and Income Statement
Profit Margin
5.45%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.15B
Net Income Avi to Common (ttm)
62.5M
Diluted EPS (ttm)
10.60
Balance Sheet and Cash Flow
Total Cash (mrq)
76.81M
Total Debt/Equity (mrq)
6.88%
Levered Free Cash Flow (ttm)
--